Pharmafile Logo

Padcev

The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Padcev in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Padcev.

47

2030 Global forecast Ranking

Recent articles on PMLiVE featuring Padcev

- PMLiVE
Pfizer’s PADCEV gets FDA approval for bladder cancer

Bladder cancer affects more than 614,000 people globally each year

- PMLiVE
Pfizer/Astellas share positive phase 3 results for Padcev in bladder cancer

Approximately 614,000 people are diagnosed with bladder cancer globally every year

- PMLiVE
Pfizer shares positive late-stage results for sasanlimab combination in bladder cancer

Approximately 10,500 people are diagnosed with bladder cancer in the UK every year

- PMLiVE
Merck’s Keytruda recommended by NICE to reduce risk of lung cancer recurrence

More than 5,000 patients in England are expected to be eligible for the anti-PD-1 therapy

- PMLiVE
Merck and Astellas/Pfizer’s bladder cancer combination receives MHRA approval

About 614,000 people are diagnosed with bladder cancer globally every year

- PMLiVE
Merck and Astellas/Pfizer’s bladder cancer combination granted EC approval

Bladder cancer is the fifth most commonly diagnosed cancer in Europe, with more than 165,000 annual cases

- PMLiVE
Astellas’ zolbetuximab combination receives positive CHMP opinion for advanced gastric cancer

Gastric cancer is currently the sixth-most common cause of cancer-related mortality in Europe

- PMLiVE
Merck and Astellas/Pfizer’s bladder cancer combination receives positive CHMP opinion

More than 165,000 new cases of bladder cancer are diagnosed in the EU every year

- PMLiVE
Date set for EU antitrust regulators to decide on Pfizer’s $43bn Seagen acquisition

The proposed transaction would mark a significant boost to the US pharma’s oncology pipeline

- PMLiVE
US FTC requests more information on Pfizer’s proposed $43bn Seagen acquisition

The transaction would mark a significant boost to Pfizer’s oncology pipeline

- PMLiVE
US government announces first set of drugs subject to Medicare inflation rebates

The move could reduce out-of-pocket costs for Medicare beneficiaries by up to $390 per dose

- PMLiVE
Pfizer to acquire Seagen for $43bn in biggest pharma transaction since 2019

The deal includes four approved medicines and Seagen’s antibody-drug conjugate technology

Data provided by GlobalData

GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.

Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.

To find out more about how our research and insights can help you, please visit  https://www.globaldata.com/who-we-are/why-globaldata/

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links